Cargando…
Controversies in the management of ESBL-producing Enterabacterales. Clinical Implications
Extended-spectrum β-lactamases (ESBL)-producing organisms currently represent a major health problem. Although recently published guidelines still consider carbapenems as the treatment of choice for ESBL-producing infections, it is necessary to find non-carbapenem β-lactams as alternatives to reduce...
Autores principales: | Maseda, Emilio, de la Rica, Alejandro Suárez |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Sociedad Española de Quimioterapia
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9717462/ https://www.ncbi.nlm.nih.gov/pubmed/36285857 http://dx.doi.org/10.37201/req/s03.10.2022 |
Ejemplares similares
-
Treatment of infections caused by carbapenemase-producing Enterobacterales
por: Íñigo, Melania, et al.
Publicado: (2022) -
New treatments for multidrug-resistant non-fermenting Gram-negative bacilli Infections
por: Chumbita, Mariana, et al.
Publicado: (2022) -
Dalbavancin
por: Barberán, José, et al.
Publicado: (2021) -
Ceftolozane-tazobactam: When, how and why using it?
por: López, Inmaculada, et al.
Publicado: (2021) -
Ceftobiprole: a clinical view
por: Pérez-Crespo, Pedro María Martínez, et al.
Publicado: (2021)